A Novel Validated HS-GC-MS method for the trace level determination of Acetyl chloride as Isopropyl acetate in various anti-cancer drug substances
Abstract
A novel, simple and precise headspace gas chromatography-mass spectrometry (HS-GC-MS) method was developed and validated for the determination of acetyl chloride (AC) in various anti-cancer drug substances like bendamustine HCl, Ibrutinib, trifluridine and abemaciclib drug substances. In this methodology, AC reacts with isopropyl alcohol and is converted into isopropyl acetate. Hence AC is quantified as Isopropyl acetate. The lower level of detection was achieved on the capillary GC column (DB-624, Fused silica capillary column; 30 m length; 0.32 mm internal diameter, coated with 6% Cyanopropylphenyl and 94% dimethyl polysiloxane stationary phase of 1.8 μm film thickness) with electron impact ionization (EI) technique by GC-MS in selective ion monitoring (SIM) mode. The mass ions were selected for the quantifier is 63 and the qualifier is 87 for isopropyl acetate. The performance of the method was assessed by evaluating the specificity, linearity, sensitivity, precision, accuracy and robustness experiments. The established limit of detection and limit of quantification values for the AC were 0.1 and 0.3 μg/g, respectively. This developed method was found to be linear with a correlation coefficient is greater than 0.999 for all four drug substances. The average recoveries of AC in bendamustine HCl, ibrutinib, trifluridine and abemaciclib were obtained 106.1, 109.0, 97.4 and 101.6%, respectively. The proposed method was validated successfully as per ICH guidelines. Hence, the proposed method can be routinely used for the quantification of AC in various anti-cancer drug substances.
Keywords:
Bendamustine HCl, Ibrutinib, Trifluridine and Abemaciclib, Acetyl chloride, HS-GC-MS, Mutagenic impurity and ValidationDOI
https://doi.org/10.25004/IJPSDR.2023.150504References
Neil O, Maryadele J, The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Merck Research Laboratories, Whitehouse Station, NJ, Merck, 2006.
Ribosepharm GmbH. Bendamustine product monograph. München, Germany, 2000.
Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine monotherapy in advanced and re-fractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol, 2001; 127(1): 48-54.
Bagchi S. Bendamustine for Advanced Sarcoma. Lancet Oncol 2007; 8(8): 674-679.
Friedberg, JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractoryindolent and transformed non-Hodgkin’s lymphoma: results from a phaseII multicenter, single-agent study;Journal of Clinical Oncology, 2008; 26(2): 204-210.
Cives M, Ciavarella S, Rizzo FM, De Matteo M, Dammacco F, Silvestris F. Bendamustine overcomes resistance to melphalan in mye- loma cell lines by inducing cell death through mitotic catastrophe; Cellular Signalling, (2013); 25(5): 1108-1117.
http://www.ncbi.nlm.nih.gov/pubmedhealth
http://www.cancer.gov/cancertopics/druginfo/fda-bendamustine-hydrochloride-indications
Pencheva I, Bogomilova A, Koseva N, Obreshkova D, Troev K. HPLC study on the stability of Bendamustine hydrochloride immobilized onto polyphosphoesters. Journal of Pharmaceutical and Biomedical Analysis, 2008; 48(4): 1143-1150.
Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. doi: 10.1158/1078-0432.CCR-07-1061.
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221.
US patent 7514444, Honigberg L, Verner E, Pan Z, Inhibitors of bruton’s Tyrosine Kinase, pharmacyclics Inc 7 April 2009.
Cameron F, Sanford M, Ibrutinib: First global approval, Drugs 2014; 74: 263-271.
Singh J, Petter RC, Kluge AF, Targeted covalent drugs of the kinase family, Curr. Opin. Chem. Biol. 2010; 14: 475-480
FDA approves Imbruvica for rare blood cancer, United States Food and Drug Administration, 2019.
Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia, Drug Pub Med 2015; 75(7):769-776.
Bagcchi, S. Ibrutinib in pretreated Waldenström's macroglobulinaemia. The Lancet Oncology, 2015; 16(5): e204.
News Release: FDA Expands Approved Use of Imbruvica for Rare Form of Non- Hodgkin Lymphoma, FDA, 2015; January 29.
Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laene A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men Drug Metab. Dispos. Pubmed., 2015; Feb: 43(2): 289-97.
https://www.drugbank.ca/drugs/DB00432
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf
Kish T, Uppal P. Trifluridine/ Tipiracil (Lonsuf) for the treatment of metastatic colorectal cancer. Pharmacy and Therapeitics. 2016; 41(5): 314-317, 325.
Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwara K and Hoff PM. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS – 102 in patients with solid tumors. Cancer. 2006; 107(6): 1383-90.
Temmink OH, Prins HJ, van Gelderorp E, Peters GJ. The Hollow Fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. 2007; Jan 15; 96 (1): 61-6.
Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K. Repeated oral dosing of TAS – 102 confers high trifluridine incorpotation into DNA and sustained anti tumor activity in mouse models. Oncology Reports, 2014; 32: 2319-2326.
Burness CB and Duggan ST. Trifluridine/Tipiracil: A Review in metastatic colorectal
cancer. Drugs, 2016; 76(14): 1393-402.
Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Prado MD, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014; 32(5): 825-37.
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017; 35(25): 2875-84.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32): 3638–46.
Johnston S, Martin M, Leo AD, Im S, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019; 5: 5.
Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Bachelot T. Hematological adverse effects in patients with breast cancer treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast cancer. 2018; 25(1): 17-27.
Ramos-Esquivel A, Hernandez-Steller H, Savard MF, Landaverde DU. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer. 2018; 25(4): 479-88.
Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, et al. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol. 2016; 78(2): 281-8.
Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK, Cronier DM. A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients. Clin Pharmacokinet. 2018; 57(3): 335-44.
Posada MM, Morse BL, Turner PK, Kulanthaivel P, Hall SD, Dickinson GL. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. J Clin Pharmacol. 2020; 60(7): 915-30.
Sahu NP, Pal C, Mandal NB, Banerjee S, Raha M, Kundu AP, Basu A, Ghosh M, Roy K, Bandyopadhyay S. Synthesis of a novel quinoline derivative, 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide--a potential antileishmanial agent. Bioorg Med Chem. 2002 Jun;10(6):1687-93. doi: 10.1016/s0968-0896(02)00046-9.
Ahn JH, Kim HM, Jung SH, Kang SK, Kim KR, Rhee SD, Yang SD, Cheon HG, Kim SS. Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4461-5. doi: 10.1016/j.bmcl.2004.06.046.
Chavan AA, Pai NR. Synthesis and biological activity of N-substituted-3-chloro-2-azetidinones. Molecules. 2007 Nov 12;12(11):2467-77. doi: 10.3390/12112467.
Müller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, DeGeorge J, De Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211. doi: 10.1016/j.yrtph.2005.12.001.
I.H.T. Guideline, Assessment and Control of DNA Reactive (Mutagenic)Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, in: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Geneva, Citeseer, 2014
ICH guideline: Impurities in New drug substances Q3A, (R2), ICH guideline; Impurities in new drug products Q3B, (R2), International Conference on Harmonisation, (2006).
Genotoxic and carcinogenic impurities in drug substances and Products; Recommended Approaches, FDA Centre for Drug Evaluation and Research, Guidance for Industry (Draft), December 03 (2008).
International Conference on Harmonization of technical requirements for registration of Pharmaceutical for human use, ICH harmonized tripartite guideline, Validation of analytical procedures: Text and methodology, Q2 (R1), step 4 (2005).
Published
Abstract Display: 839 
PDF Downloads: 383 
